Finch, Amy
Clark, Roderick http://orcid.org/0000-0001-7987-375X
Vesprini, Danny
Lorentz, Justin http://orcid.org/0000-0002-8177-2429
Kim, Raymond H.
Thain, Emily
Fleshner, Neil
Akbari, Mohammad R.
Cybulski, Cezary
Narod, Steven A. http://orcid.org/0000-0001-5798-0626
Article History
Received: 6 October 2021
Accepted: 13 May 2022
First Online: 22 June 2022
Competing interests
: Dr. Neil Fleshner has received consulting fees from Amgen, Janssen, Astellas, Bayer, Sanofi, Abbvie, Ferring, has stock holdings in POINT Biopharma and Verity pharmaceuticals and is the Chief Medical Officer for Verity pharmaceuticals and POINT Biopharma. Dr. Fleshner holds research grants (paid to the institution) from Janssen, Astellas, Bayer, Sanofi, Nucleix, Progenix, SpectraCure AB, Bavarian Nordic. Dr. Mohammad Akbari holds stock and other ownership interests in Genewise Inc. All other authors have no competing interests to report.